Jeito Capital closed its second fund at $1.2 billion (€1 billion+), targeting 15 to 20 European clinical-stage biopharma companies. The firm said the larger pool allows higher average ticket sizes (up to about €150 million per company) and follow-on support, aiming to keep strong biotechs private longer amid investor and patent-cycle pressures. Jeito’s fundraising highlights sustained European private-market demand for late-entry capital and structured support for translational and clinical execution.